Pluri (NASDAQ:PLUR – Get Free Report) and Adverum Biotechnologies (NASDAQ:ADVM – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.
Analyst Ratings
This is a summary of recent recommendations and price targets for Pluri and Adverum Biotechnologies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pluri | 0 | 0 | 0 | 0 | 0.00 |
| Adverum Biotechnologies | 0 | 1 | 5 | 0 | 2.83 |
Adverum Biotechnologies has a consensus price target of $27.83, indicating a potential upside of 542.80%. Given Adverum Biotechnologies’ stronger consensus rating and higher possible upside, analysts clearly believe Adverum Biotechnologies is more favorable than Pluri.
Volatility & Risk
Profitability
This table compares Pluri and Adverum Biotechnologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pluri | -4,184.28% | -917.18% | -82.85% |
| Adverum Biotechnologies | N/A | -65.14% | -40.52% |
Institutional and Insider Ownership
16.6% of Pluri shares are held by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are held by institutional investors. 10.2% of Pluri shares are held by insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Pluri and Adverum Biotechnologies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pluri | $330,000.00 | 70.43 | -$20.89 million | ($6.03) | -0.69 |
| Adverum Biotechnologies | $3.60 million | 25.02 | -$117.17 million | ($5.99) | -0.72 |
Pluri has higher earnings, but lower revenue than Adverum Biotechnologies. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.
Summary
Adverum Biotechnologies beats Pluri on 9 of the 14 factors compared between the two stocks.
About Pluri
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
About Adverum Biotechnologies
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Receive News & Ratings for Pluri Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluri and related companies with MarketBeat.com's FREE daily email newsletter.
